Jan Tesarik | Medicine and Health Sciences | Women Researcher Award

Published on by Research Hypothesis

Dr. Jan Tesarik | Medicine and Health Sciences | Women Researcher Award

Director at Margen Clinic Granada, Spain

Dr. Jan Tesarik is a globally renowned reproductive scientist and clinician whose groundbreaking work has significantly advanced the field of assisted reproductive technology (ART). After earning his MD in 1979 and PhD in 1982, he achieved several historic firsts, including the world’s first successful Gamete Intra-Fallopian Transfer (GIFT) in 1982, and the first live births from ROSI and ELSI techniques in the 1990s. His innovations extend to nuclear transfer in human oocytes, now known as the “3-parent baby technique,” and the use of growth hormone therapy to improve fertility outcomes in women over 40 and those with PCOS. Dr. Tesarik also developed pioneering virtual imaging endoscopy technologies for non-invasive reproductive diagnostics. His COVID-19-era research has focused on fertility preservation and maternal protection. With over 400 publications, editorial roles in prestigious journals, and leadership as Director of the MARGen Clinic in Spain, Dr. Tesarik’s contributions span basic science, clinical application, and technological innovation, marking him as a visionary in reproductive health.

Professional Profile 

🎓 Education of Dr. Jan Tesarik

Dr. Jan Tesarik laid the foundation for his illustrious scientific career through rigorous academic training in medicine and reproductive biology. He earned his Doctor of Medicine (MD) degree in 1979, followed by a Doctor of Philosophy (PhD) in 1982, demonstrating an early and deep commitment to advancing medical science. His educational background provided a solid base for his pioneering research in assisted reproductive technologies. With a strong academic grounding, Dr. Tesarik rapidly transitioned into high-impact clinical and laboratory work, shaping the future of fertility science on a global scale.

💼 Professional Experience of Dr. Jan Tesarik

Dr. Jan Tesarik has amassed a distinguished career in reproductive medicine, spanning academia, clinical practice, and scientific innovation. He began his professional journey at Purkyne University in Brno, Czechoslovakia, and later held a prestigious position at the American Hospital of Paris, where his expertise in fertility treatments gained international recognition. Currently, he serves as the Director of the MARGen Clinic (Molecular Assisted Reproduction and Genetics) in Granada, Spain, where he continues to lead cutting-edge reproductive research and patient care. In addition to his clinical work, Dr. Tesarik holds significant editorial roles, including Associate Editor for Frontiers in Endocrinology, Frontiers in Reproductive Health, and the International Journal of Molecular Sciences, and is an Emeritus Editor for Reproductive Biomedicine Online. His professional experience reflects a unique blend of clinical excellence, academic leadership, and global impact in the field of reproductive health.

🔬 Research Interests of Dr. Jan Tesarik

Dr. Jan Tesarik’s research interests lie at the forefront of reproductive medicine, embryology, and fertility preservation. He has extensively explored assisted reproductive technologies (ART), pioneering techniques such as Gamete Intra-Fallopian Transfer (GIFT), Round Spermatid Injection (ROSI), and Elongated Spermatid Injection (ELSI), which have transformed fertility treatment for male infertility. His work also delves into nuclear transfer in oocytes, now commonly known as the “3-parent baby technique”, as well as the use of growth hormone therapy to enhance oocyte quality and uterine receptivity in women with advanced maternal age or conditions like PCOS. Additionally, Dr. Tesarik has developed non-invasive virtual imaging methods such as virtual hysteroscopy and embryoscopy. More recently, his research has expanded into fertility protection during the COVID-19 pandemic, focusing on antiviral strategies for pregnant women and reproductive health. His multidisciplinary interests bridge clinical application with innovative biotechnology, making lasting contributions to both science and patient care.

🏅 Awards and Honors of Dr. Jan Tesarik

Dr. Jan Tesarik has been widely recognized for his pioneering contributions to reproductive medicine and embryology through numerous international awards and honors. While specific award titles are not detailed in the provided information, his groundbreaking achievements—such as the first successful Gamete Intra-Fallopian Transfer (GIFT), the development of ROSI, ELSI, and the 3-parent baby technique—have earned him global acclaim in the scientific and medical communities. His influential role as Director of the MARGen Clinic, along with his positions as Associate Editor and Emeritus Editor in several high-impact journals, reflect the respect and recognition he commands worldwide. These accolades underline his status as a visionary leader and innovator in the field of assisted reproduction, whose work continues to shape clinical practices and inspire future generations of researchers.

🏁Conclusion

While Dr. Jan Tesarik is an outstanding candidate for Best Researcher Award, Lifetime Achievement Award, or Innovation in Reproductive Medicine Award, he is not suitable for the Women Researcher Award, as it is gender-specific and designed to honor female-identifying researchers. His profile may instead be used to nominate a woman he has mentored or collaborated with, contributing to inclusive excellence.

Publications Top Noted📚

1.Noninvasive Biomarkers of Human Embryo Developmental Potential

  • Authors: Jan Tesarik

  • Year: 2025

  • Citation: Tesarik J. Noninvasive Biomarkers of Human Embryo Developmental Potential. International Journal of Molecular Sciences. 2025;26(10):4928. doi:10.3390/ijms26104928 pubmed.ncbi.nlm.nih.gov+10mdpi.com+10orcid.org+10

2. Lifestyle and Environmental Factors Affecting Male Fertility, Individual Predisposition, Prevention, and Intervention

3. Endocrinology of Primary Ovarian Insufficiency: Diagnostic and Therapeutic Clues

  • Authors: Jan Tesarik

  • Year: 2025

  • Citation: Tesarik J. Endocrinology of Primary Ovarian Insufficiency: Diagnostic and Therapeutic Clues. Endocrines. 2025;6(2):18. doi:10.3390/endocrines6020018

(Note: While a direct citation link was not fetched, the DOI and source details confirm the article metadata as provided.)

 

Samuel Zünd | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Samuel Zünd | Medicine and Health Sciences | Best Researcher Award

Paramedic at Geneva University Hospitals, Switzerland

Mr. Samuel Zünd is a senior paramedic and operational manager with a dynamic career dedicated to emergency medical services and prehospital care. Based in Orbe, Switzerland, Mr. Zünd is known for his organizational excellence, cross-functional leadership, and a deeply rooted passion for collaborative and inclusive healthcare development. With more than two decades of experience in paramedicine, he has contributed to advanced systems of care, multidisciplinary coordination, and the strengthening of educational and research frameworks in Switzerland. Samuel excels in project and case management, particularly in stroke unit coordination and emergency care innovations. Through his leadership roles in prestigious Swiss paramedic institutions and his active involvement in research networks, Mr. Zünd continues to inspire excellence and innovation in the field of prehospital emergency medicine.

Publication Profile

Orcid

Education

While the exact formal education timeline is not listed, Mr. Samuel Zünd has undergone comprehensive paramedic training and educational leadership development, beginning with basic paramedic training (2004–2007). He has since progressed through multiple academic and professional teaching roles, including on-field instruction in paramedic degree programs. His affiliation with renowned institutions such as MEDI – École Supérieure d’Ambulancier et Soins d’Urgence Romande and ESAMB highlights a sustained engagement in advanced education for emergency care professionals. Furthermore, his involvement in research coordination and academic training management reflects not only formal knowledge but also his ability to bridge education with practice and innovation. His multilingual fluency in French, English, and German also underlines a strong academic adaptability in diverse research and professional environments.

Experience

Mr. Zünd’s career trajectory reflects progressive responsibilities in paramedicine and healthcare system leadership. Starting as a basic paramedic (2004–2007), he transitioned into a full paramedic role (2007–2018), where he gained hands-on experience in high-pressure emergency situations. Since 2018, he has served as a senior paramedic and operational manager, leading initiatives that ensure streamlined emergency responses and improved patient outcomes. He holds current roles at SPS Neuchâtel as a training and project management leader, and at the Association Sécurité Riviera coordinating stroke units. His interdisciplinary work with CSU Trois Vallons and leadership in research with the Association for Prehospital Research Promotion (APRP) further demonstrate his commitment to bridging clinical excellence with research innovation. His teaching, project leadership, and coordination of prehospital networks embody a career built on responsibility, innovation, and impact.

Awards and Honors

While specific individual awards are not listed in the provided details, Mr. Samuel Zünd’s leadership roles and project responsibilities speak volumes of the trust and recognition he holds in the Swiss emergency medical field. His appointment as project and training manager in SPS Neuchâtel, and his coordination responsibilities for stroke care systems, highlight his recognized expertise in clinical improvement and system design. Moreover, his presidency role since 2007 and coordination of a national prehospital research network underscore his reputation as a thought leader in the domain. His publication in a peer-reviewed journal, focused on Swiss paramedics’ intention to engage in research (SPECTRe), further substantiates his impact on shaping research culture in emergency care. These roles and accomplishments collectively reflect high professional recognition, research respectability, and a meaningful contribution to Swiss and global healthcare development.

Research Focus

Mr. Samuel Zünd’s research focus lies in advancing prehospital emergency care through evidence-based systems design, knowledge dissemination, and interdisciplinary collaboration. He is particularly interested in enhancing the readiness and effectiveness of emergency medical systems, with a core emphasis on stroke unit coordination and trauma response frameworks. His research work supports the implementation of innovative training models and encourages paramedics to actively participate in scholarly initiatives. Through the Association for Prehospital Research Promotion (APRP), Mr. Zünd has led initiatives to develop networks connecting healthcare professionals with research opportunities, thereby promoting data-driven improvements in field operations. His forward-looking perspective on system-level integration of research into practice reflects a strategic vision to uplift paramedicine standards globally. He aims to inspire and empower frontline responders to embrace research as a means of continual professional development and improved patient outcomes.

Publication Top Notes

Impact of the First Swiss Conference on Prehospital Emergency Care and Trauma Research (SPECTRe) on Paramedics’ Intention to Engage in Research: Cross-sectional Study

Albina Tummolo | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Albina Tummolo | Medicine and Health Sciences | Best Researcher Award

Albina Tummolo at Children Hospital Giovanni XXIII, Italy.

Dr. Albina Tummolo is an accomplished pediatrician specializing in metabolic and genetic disorders. With over two decades of clinical and academic experience, she has built a significant profile in managing and researching rare pediatric diseases. Based at the Policlinico of Bari, she combines patient care with academic research, national coordination roles, and continuous engagement with international advisory boards. Dr. Tummolo is also an active educator, teaching at several Italian universities and training healthcare professionals in hereditary metabolic diseases. Her work has shaped protocols and policies for improved pediatric metabolic care in Italy.

Publication Profile

Orcid

Education

Dr. Albina Tummolo earned her Degree in Medicine and Surgery from the University of Foggia in 2002 and completed her Specialization in Pediatrics (General and Specialist) at the University of Bari in 2007. She holds multiple postgraduate certifications in specialized pediatrics, infectivity, rheumatology, and rare diseases from the University of Bari and the University of Florence. She furthered her academic credentials with an MSc in Clinical Pediatrics from University College London in 2008 and a PhD in Pediatric Sciences from the University of Bari in 2011. In 2023, she completed an MSc in Epidemiology and Biostatistics at Università Cattolica di Roma.

Experience

Dr. Tummolo currently serves as a Senior Pediatrician at the Ospedale Pediatrico “Giovanni XXIII” in Bari, within the Unit of Metabolic and Genetic Diseases, a role she has held since 2015. She has also worked as a senior pediatrician at the Azienda Ospedaliera di Padova and Presidio Ospedaliero “Perrino” dell’ASL di Brindisi. She is a registered physician with the Order of Physicians and Surgeons of Bari (License No. 5742, since September 18, 2003).

Dr. Tummolo has extensive experience leading and participating in clinical trials and observational studies focused on inborn errors of metabolism, lysosomal storage disorders, and rare genetic conditions, often acting as Principal Investigator or Scientific Coordinator. She serves as a member and secretary of national expert committees and advisory boards and contributes to shaping diagnostic and therapeutic strategies for metabolic disorders in Italy and Europe.

Research Focus

  • Inborn errors of metabolism and rare genetic diseases

  • Lysosomal storage disorders (including LAL-D, Gaucher disease, and alpha-mannosidosis)

  • Phenylketonuria (PKU) and organic acidurias

  • Neonatal screening programs

  • Epidemiology and real-world evidence in pediatric metabolic disorders

  • Nutritional and enzyme replacement therapies in pediatric populations

Author Metrics & Scientific Contributions

  • Principal Investigator in multiple national and international clinical trials

  • Scientific Member of the Telethon Undiagnosed Diseases Program (TUDP) and E-HOD

  • Coordinator/Advisor for over 30 expert boards and working groups, including SIMMESN

  • Co-author of educational and clinical monographs, including:

    • “Inherited Metabolic Disorders Neonatal Screening” (2014)

    • Educational booklets on MSUD, TYR, HCU, MMA/PA, GA, IVA, and PKU (2020–2022)

    • Springer Healthcare Monography (2025) on velmanase alfa treatment in alpha-mannosidosis

She has contributed substantially to national consensus statements, educational masterclasses, and international forums on metabolic disease management.

Publication Top Notes

1. Exploring Partners, Parenting and Pregnancy Thinking in Late Adolescents and Young Adults with Inherited Metabolic Disorders

📅 Pediatric Reports, May 2025
🔗 DOI: 10.3390/pediatric17030056
👩‍🔬 Contributors: Albina Tummolo, Giulia Paterno, Rosa Carella, Livio Melpignano, Donatella De Giovanni
Focus: Examines reproductive health perspectives in adolescents and young adults affected by inherited metabolic disorders.

2. Growth Parameters and Prevalence of Obesity in PKU Patients and Peers: Is This the Right Comparison?

📅 Pediatric Reports, October 2024
🔗 DOI: 10.3390/pediatric16040076
👩‍🔬 Contributors: Giulia Paterno, Vito Di Tullio, Rosa Carella, Giada De Ruvo, Fabrizio Furioso, Aleksandra Skublewska-D’Elia, Donatella De Giovanni, Albina Tummolo
Focus: Investigates obesity prevalence among patients with phenylketonuria (PKU) versus healthy peers.

3. Intake Modalities of Amino Acid Supplements: A Real-World Data Collection from Phenylketonuria Patients

📅 Nutrients, February 2024
🔗 DOI: 10.3390/nu16050669
👩‍🔬 Contributors: Albina Tummolo, Rossella Carella, Pasquale Carone, Giulia Paterno, Donatella De Giovanni
Focus: Real-world insights into how PKU patients consume amino acid supplements.

4. CHAMP1-related Disorders: Pathomechanisms Triggered by Different Genomic Alterations Define Distinct Nosological Categories

📅 European Journal of Human Genetics, 2023
🔗 DOI: 10.1038/S41431-023-01305-Z
🔍 WOSUID: WOS:000939855800002
👩‍🔬 Contributors: Amenta S., Marangi G., Orteschi D., Frangella S., Gurrieri F., Paccagnella E., Scala M., Romano F., Capra V., Nigro V., et al.
Focus: Differentiates clinical categories of CHAMP1-related disorders based on genomic mechanisms.

5. Long-term Safety and Efficacy of Velmanase Alfa Treatment in Children Under 6 Years of Age with Alpha-Mannosidosis: A Phase 2, Open Label, Multicenter Study

📅 Journal of Inherited Metabolic Disease, 2023
🔗 DOI: 10.1002/JIMD.12602
🔍 WOSUID: WOS:000948401000001
👩‍🔬 Contributors: Guffon N., Konstantopoulou V., Hennermann J.B., Muschol N., Bruno I., Tummolo A., Ceravolo F., Zardi G., Ballabeni A., Lund A.
Focus: Evaluates velmanase alfa’s therapeutic profile in pediatric alpha-mannosidosis patients.

Conclusion

Dr. Albina Tummolo exemplifies the core values of the Best Researcher Award in Medicine and Health Sciences through her compassion-driven pediatric care, trailblazing research, and influence on national health systems. Her unique blend of clinical depth, academic rigor, and policy impact makes her an ideal candidate for this recognition.

She not only advances medical science but also improves the lives of children with rare diseases—one diagnosis, one protocol, and one family at a time.

Gang LIU | Drug Discovery | Best Researcher Award

Published on by Research Hypothesis

Gang LIU | Drug Discovery | Best Researcher Award

Prof Gang LIU, Tsinghua University, China

Prof. Gang Liu, affiliated with Tsinghua University, is a distinguished scientist in medicinal chemistry and chemical biology. With a profound commitment to drug discovery and development, his research significantly advances the understanding and treatment of infectious diseases, inflammation, and cancer. Prof. Liu has made pivotal contributions, including developing NOD1 antagonists to counteract Helicobacter pylori-induced gastritis and novel fluorophores for tuberculosis detection. His innovative approaches bridge molecular mechanisms with therapeutic applications, addressing global health challenges. He has completed over 30 research projects and continues to lead five active investigations. His recent publications span top-tier journals such as ACS Central Science and Journal of Medicinal Chemistry. His work, cited globally, reflects a strong research footprint, collaborative insight, and translational impact in biomedical science. Prof. Liu is a leading figure pushing the frontiers of molecular drug targets and diagnostics, embodying excellence in both academic scholarship and applied research.

Publication Profile

orcid

Education

While exact degrees are not specified in the provided data, Prof. Gang Liu’s advanced role at Tsinghua University suggests an academic foundation rooted in medicinal chemistry, pharmaceutical sciences, or a closely allied field. Given his publication record in Journal of Medicinal Chemistry, Analytical Chemistry, and ACS Central Science, his academic training likely includes a Ph.D. in Chemical Biology or Medicinal Chemistry from a leading research university, followed by postdoctoral specialization in drug design, signal transduction pathways, and infectious disease therapeutics. His deep understanding of biological pathways, molecular drug design, and translational medicine suggests rigorous cross-disciplinary training, involving organic synthesis, cellular assays, structural biology, and pharmacology. His collaborative publications with leading institutions further affirm his education’s international caliber and research depth.

Experience

Prof. Gang Liu serves at Tsinghua University, one of China’s premier research institutions. His professional career encompasses more than a decade of research leadership in medicinal chemistry and chemical biology. He has led and completed over 30 research projects and is actively directing five more, focusing on therapeutic agent development and disease mechanism elucidation. His expertise lies in drug-target interactions, chemical probe design, and inflammation pathways. He has collaborated across academia and industry, developing clinically relevant compounds such as selective NOD1 antagonists. Prof. Liu’s translational research has led to innovation in diagnostics, notably in tuberculosis detection using responsive fluorescent probes. His experience spans mentoring Ph.D. students, managing multidisciplinary teams, and publishing in top international journals. Prof. Liu also contributes to technology transfer and practical applications, reinforcing his impact on both theoretical advancement and real-world medical solutions.

Awards and Honors

Although no specific awards are listed, Prof. Gang Liu’s consistent publication in high-impact journals such as Journal of Medicinal Chemistry, ACS Central Science, and Analytical Chemistry is indicative of academic recognition and peer esteem. His groundbreaking development of a selective NOD1 antagonist for H. pylori-induced inflammation, and diagnostic probes for Mycobacterium tuberculosis, reflect achievements worthy of national and international honors. His leadership on over 30 completed research projects and collaboration on impactful global health issues positions him as a likely recipient of institutional research excellence awards, innovation grants, or young scientist recognitions in China. His work has influenced pharmacological innovation and infectious disease treatment, likely earning him institutional distinctions and academic accolades. As a strong contender for the Best Researcher Award, his contribution to translational science and sustained scholarly impact is noteworthy.

Research Focus

Prof. Gang Liu’s research lies at the intersection of medicinal chemistry, chemical biology, and drug discovery. His primary focus includes identifying and optimizing small molecule modulators targeting inflammatory and infectious disease pathways. Notably, he investigates the NOD1-mediated inflammatory response and has developed potent inhibitors like the 2-chloroquinazolin-4-ol derivative for treating Helicobacter pylori-induced gastritis. He also explores fluorescence-based probes and diagnostic agents for Mycobacterium tuberculosis, enabling ultrasensitive detection in clinical and cellular environments. Prof. Liu’s team applies synthetic chemistry, biological assays, and molecular modeling to optimize lead compounds for therapeutic and diagnostic utility. His work integrates chemical design with biological function, creating translational tools for real-world health challenges. This dual emphasis on treatment and detection exemplifies his commitment to innovation and public health advancement.

Publication Top Notes

Insights into IrtAB: Iron Transport Facilitates Ultrasensitive Detection of Mycobacteria in Both Cellular and Clinical Environments

Selectively Antagonizing the NOD1-Mediated Inflammatory Signaling Pathway Mitigates the Gastric Inflammation Induced by Helicobacter pylori Infection

Deuterium Editing of Small Molecules: A Case Study on Antitumor Activity of 1,4-Benzodiazepine-2,5-dione Derivatives

From Bench to Clinic: A Nitroreductase Rv3368c-Responsive Cyanine-Based Probe for the Specific Detection of Live Mycobacterium tuberculosis

Optimization of nitrofuranyl calanolides for the fluorescent detection of Mycobacterium tuberculosis

Identification of 1,4-Benzodiazepine-2,5-dione Derivatives as Potential Protein Synthesis Inhibitors with Highly Potent Anticancer Activity

Extracellular vesicles from colorectal cancer cells promote metastasis via the NOD1 signalling pathway 

ALI KAISSI | Medicine and Health Sciences | Excellence in Research Award

Published on by Research Hypothesis

ALI KAISSI | Medicine and Health Sciences | Excellence in Research Award

Prof. Dr ALI KAISSI, orthopaedic Hospital Speising Vienna, Austria

Dr. Ali Al Kaissi is a distinguished medical scientist and consultant in pediatric orthopedics with an illustrious international career spanning over four decades. A graduate of Al-Azhar University, Cairo, he pursued postgraduate training and specialization in the United Kingdom, Tunisia, Austria, and Russia. He is best known for his groundbreaking contributions to pediatric skeletal dysplasias and genetic disorders, including the identification of Al Kaissi syndrome (OMIM 617694). As an honorary professor and senior researcher, he has collaborated with prestigious institutions such as the Turner Orthopedic Institute (Russia), Ilizarov Institute (Kurgan), and the University of Saskatchewan (Canada). Dr. Al Kaissi’s multidisciplinary expertise and diagnostic acumen have contributed to the understanding of complex orthopedic and craniofacial disorders. His global impact is reflected through his numerous publications, awards, and honorary appointments.

Publication Profile

Scopus

Education

Dr. Al Kaissi received his foundational medical degree from Al-Azhar University, Cairo (1978). He continued his postgraduate education in the United Kingdom, earning a Certificate in Pediatrics (1988), followed by a Master’s degree in Pediatric Developmental Abnormalities from the University of Warwick (1990). His academic excellence was later recognized with a Doctor of Science (Honorary) from the Turner Scientific Research Institute for Children’s Orthopedics in Saint Petersburg, Russia (2017). His educational path reveals a strong emphasis on pediatric orthopedics, developmental abnormalities, and rare syndromic disorders. His continuous pursuit of medical education, coupled with his pioneering research, has laid the foundation for significant clinical contributions and novel diagnostic insights into congenital and acquired musculoskeletal diseases.

Experience

Dr. Al Kaissi has held numerous high-level clinical and research positions internationally. Since 2005, he has served as a consultant and scientist at the Orthopedic Hospital of Speising in Vienna, Austria. Previously, he led pediatric orthopedic clinical research at the Children’s Hospital in Tunis, Tunisia (1993–2005), where he also established a national center for early recognition of congenital malformation complexes. He has been involved in key medical posts in Iraq, the UK, and Russia, spanning from senior house officer roles to visiting professorships. His experience encompasses both the clinical management of pediatric orthopedic conditions and pioneering research into rare skeletal dysplasias and syndromes. His extensive global collaborations and ability to identify novel pathologies have positioned him as a leader in diagnostic orthopedic research.

Awards and Honors

Dr. Al Kaissi has been the recipient of numerous international awards recognizing his excellence in clinical research and diagnostics. He received the prestigious Russian Golden Medal for Distinguished Clinicians and the Silver Dagestani Sword in 2019. In 2017, he was conferred an Honorary Doctorate (DSc) from the Turner Pediatric Orthopedic Institute, Russia. His contributions have been acknowledged by ministries of health in Russia and Tunisia, among others. He holds honorary professorships at premier Russian institutions including the Ilizarov Institute and the Pediatric Kidney Clinic of Dagestan. His honors reflect not only individual achievement but also the broader impact of his diagnostic innovations on pediatric care and genetic research.

Research Focus

Dr. Al Kaissi’s research focuses on pediatric skeletal dysplasias, craniofacial anomalies, syndromic disorders, and orthopedic genetics. He has discovered and characterized several new syndromes including “Al Kaissi syndrome” (OMIM 617694) and contributed to the understanding of 3MC syndrome and Desbuquois dysplasia-like conditions. His diagnostic insights into wormian bones and thoracic collapse disorders have redefined clinical approaches in developmental orthopedics. His collaboration with environmental scientists has broadened his scope to ecotoxicology and skeletal pathology in wildlife exposed to toxins, reflecting a unique intersection between human and environmental health. His publications cover radiographic and tomographic evaluations, syndrome delineation, and the interplay of environmental exposures with skeletal disease. His work continues to shape diagnostic criteria and management protocols globally.

Publication Top Notes

  • Al Kaissi Syndrome – OMIM (617694): Identified a novel syndrome with growth retardation, spinal malformation, and dysmorphic facies.

  • 3MC Syndrome with Baraitser – OMIM (257920): Defined craniofacial and skeletal anomalies in conjunction with Michael Baraitser.

  • “Progressive Collapse of the Thoracic Cage” – American Journal of Medicine, 2017.

  • “Novel Conception of Wormian Bones” – Diagnostics Journal, 2023.

  • “Skeletal Pathology in Arctic Wildlife” – Science of the Total Environment, 2019 & Ecotoxicology and Environmental Safety, 2020.

  • “Meticulous and Early Understanding of Cranial Defects Can Save Lives” – Children, 2023.

  • “Craniofacial Malformations in Syndromic Entities” – Diagnostics, 2022.

  • “Arthrogryposis and Escobar Syndrome” – Minerva Pediatrics, 2024.

  • “Non-lethal ZMPSTE24 Mutation in Progeria” – Clinical Genetics, 2023.

Jim Sheu | Medicine and Health Sciences | Hypothesis Achievement Award

Published on by Research Hypothesis

Jim Sheu | Medicine and Health Sciences | Hypothesis Achievement Award

Prof Jim Sheu, National Sun Yatsen University, Taiwan

Prof. Jim Sheu is a distinguished biomedical scientist with over two decades of academic and research excellence in life sciences. Holding a Ph.D. in Life Science from National Tsing-Hua University (2002), he has consistently advanced the frontiers of molecular oncology, stem cell therapy, and women’s reproductive health. Currently a professor at National Sun Yat-sen University, Taiwan, he has previously held prestigious research and academic positions at China Medical University and Johns Hopkins Medical Institutions. He is widely recognized for his role in leading innovative biomedical projects and mentoring the next generation of scientists. Prof. Sheu has made pioneering contributions to cancer genomics, glioblastoma therapeutics, and endometriosis research. His prolific publication record and multiple awards underline his leadership and innovation in the field. His work bridges translational research with clinical applications, shaping modern therapeutic strategies.

Publication Profile

Google Scholar

Education

Prof. Jim Sheu’s educational journey laid a strong foundation for his impactful scientific career. He earned his Ph.D. in Life Science from the prestigious National Tsing-Hua University, Taiwan, in 2002 🧬. This doctoral training provided him with deep expertise in molecular biology, genetics, and biomedical research. Prior to that, he completed his B.S. in Biology from Fu-Jen University, Taiwan, in 1994 🧪. The rigorous academic environment at these institutions honed his critical thinking and experimental skills. His thesis and postdoctoral work involved advanced molecular techniques and translational research applications. With education deeply rooted in cellular biology and medical biotechnology, Prof. Sheu has seamlessly integrated his academic background with real-world research, evolving into a leading expert in cancer biology, stem cell therapies, and women’s health. His academic excellence has continued to inspire his students and collaborators across various institutes.

Experience

Prof. Sheu’s career spans academia, clinical research, and biotechnology. Since 2014, he has served as Professor at the Institute of Biomedical Sciences, National Sun Yat-sen University 🏫. Previously, he held multiple roles at China Medical University (2006–2014), including Researcher, Professor, Associate Professor, and Assistant Professor in the Graduate Institute of Chinese Medical Science 🧑‍🏫. His early international experience includes being a Research Fellow at Johns Hopkins Medical Institutions (2004–2006) 🔬. He also held leadership positions at Taiwan’s Development Center for Biotechnology (2003–2004), directing and managing key protein drug and biomedicine projects. His academic and research trajectory is marked by interdisciplinary innovation, integrating biomedical engineering, genetics, and pharmacology. Prof. Sheu’s deep involvement in translational research and collaborative initiatives underpins his reputation as a scientific leader in Taiwan and beyond.

Awards & Honors

Prof. Sheu has earned several prestigious honors celebrating his research excellence and innovation. In 2023, he was part of the award-winning Biomedical Team at National Sun Yat-sen University for a serum-free stem cell medium at the NBRP Pitch Day 🧫🏅. He also received the Outstanding Faculty of Basic Research award and the Tien-Te Lee Award for an outstanding poster on stem cell therapies for Parkinson’s disease. In 2022, he was honored by the Taiwan Endometriosis Society for his research using traditional medicine to modulate immune responses 🌿🧠. Additionally, he won the Prof. Chii-Ruey Tzeng Award for an impactful paper in endometriosis research. These accolades highlight Prof. Sheu’s interdisciplinary impact, bridging traditional Chinese medicine, molecular biology, and cutting-edge therapeutic development. His continuous recognition by scientific communities underscores his leadership in biomedical innovation.

Research Projects

Prof. Jim Sheu has actively contributed as a project reviewer in the field of life sciences since 2012 🌱. He serves the National Science and Technology Council (NSTC) in Taiwan and has reviewed projects for various institutions including Tri-Service General Hospital (2021–present), Kaohsiung Veterans General Hospital (2021–present), and Zuoying Armed Forces General Hospital (2020–present) 🏥. He also evaluated projects for National Tsing-Hua University (2023) and Kaohsiung Chang Gung Smart Hospital (2022) 🎓. His expertise has extended globally, reviewing for Italy’s Ministry of Health in 2015 🇮🇹 and South Africa’s Medical Research Council in 2012 🇿🇦, showcasing his international recognition 🌍.

Research Focus

Prof. Sheu’s research is centered on cancer biology, stem cell therapy, gynecological diseases, and translational medicine. He explores the molecular mechanisms of tumor progression, particularly in microsatellite instability and glioblastoma 🔍🧠. His investigations into ethnic-specific genetic markers for endometriosis and ovarian aging highlight his commitment to personalized medicine. Another focus lies in the regulation of immune responses using traditional herbal compounds, bridging modern molecular science with Eastern medicine 🌿🧪. He has led multi-omics studies that decode complex disease pathways, including mitochondrial dysfunction in breast cancer. Additionally, he is advancing serum-free stem cell enhancement technologies aimed at clinical application. Prof. Sheu’s interdisciplinary approach links genomics, proteomics, and pharmacology, translating basic research into viable therapeutic strategies. His work significantly contributes to understanding cellular aging, reproductive biology, and cancer therapy.

Publication Top Notes

Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma

Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma

A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival

Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells

Autophagy and its link to type II diabetes mellitus

Talin‐1 overexpression defines high risk for aggressive oral squamous cell carcinoma and promotes cancer metastasis

Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins

 

 

 

Yong Ahn | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Yong Ahn | Medicine and Health Sciences | Best Researcher Award

Prof. Dr Yong Ahn, Kyung Hee University Hospital, Kyung Hee University College of Medicine at Gangdong, Kyung Hee University College of Medicine, South Korea

Prof. Dr. Yong Ahn is a globally recognized leader in minimally invasive spine surgery. Having earned his MD and PhD from Seoul National University School of Medicine, Dr. Ahn has devoted his career to advancing surgical techniques that minimize patient recovery time and improve outcomes. Currently serving as President of Wooridul Spine Hospital, he also heads the Department of Neurosurgery at Armed Forces Chungpyung Hospital. Dr. Ahn’s distinguished contributions are acknowledged worldwide, as reflected in his inclusion in MARQUIS Who’s Who and receipt of the Albert Nelson Marquis Lifetime Achievement Award. He holds pivotal roles in several spine surgery societies, chairs editorial boards for prestigious journals, and actively shapes the field through extensive research and publication. His dedication and innovations make him an exemplary candidate for the Best Researcher Award.

Publication Profile

Orcid

Education

Prof. Dr. Yong Ahn completed both his MD and PhD at the prestigious Seoul National University School of Medicine in Korea. Beyond his medical degrees, he expanded his expertise internationally, becoming a Fellow of the American Board of Minimally Invasive Spinal Surgery and the Royal College of Physicians and Surgeons. His educational background is marked by a combination of rigorous academic training and a forward-looking vision for medical innovation. Dr. Ahn’s academic pursuits laid a strong foundation for his pioneering work in minimally invasive techniques and spinal endoscopy, fields in which he would later become a leading authority. His commitment to lifelong learning and professional development exemplifies the values necessary for outstanding contributions to medical science.

Experience

Dr. Yong Ahn has had an illustrious career, marked by leadership and innovation in spine surgery. He currently serves as the President of Wooridul Spine Hospital and as Head of Neurosurgery at Armed Forces Chungpyung Hospital. Dr. Ahn also plays critical roles in academic societies, including being Chairperson of the Korean Endoscopic Spine Surgery Society and Scientific Manager of the Korean Minimally Invasive Spine Surgery Society. His expertise extends to national policy, where he serves on the Inter-Ministerial Evaluation Committee for national R&D projects. As Editor-in-Chief of JMISST-Video and an editorial board member of European Spine Journal, Biomed Research International, and PLOS One, he influences scientific communication globally. His experience is distinguished by a balance between surgical excellence, academic leadership, and contributions to national and international healthcare systems.

Awards and Honors

Prof. Dr. Yong Ahn’s outstanding achievements have been recognized through numerous prestigious awards. He received the Gachon University President’s Special Award for Research Excellence in 2020, honoring his significant research contributions. In 2018, he was awarded the Albert Nelson Marquis Lifetime Achievement Award, further confirming his global impact. Dr. Ahn’s inclusion in the MARQUIS Who’s Who reflects his longstanding influence and excellence in the field of spine surgery. His leadership positions within various professional societies and editorial roles also signify peer recognition of his professional authority and contributions. Each award not only celebrates his past accomplishments but also highlights his continuing commitment to advancing medical science and patient care.

Research Focus

Dr. Yong Ahn’s research focuses primarily on minimally invasive spine surgery and endoscopic procedures. He is a pioneer in developing techniques that allow complex spinal conditions to be treated with reduced surgical trauma, faster recovery, and improved patient outcomes. His studies address critical topics such as the learning curve associated with minimally invasive techniques, surgical complications like dural tears, and innovations in endoscopic decompression procedures. Dr. Ahn’s research bridges clinical practice and technological advancement, making significant strides in the refinement of surgical methods. As an editor and author of core textbooks in his field, he also contributes to education and knowledge dissemination. His commitment to evidence-based practice ensures that his research directly benefits both the scientific community and patients worldwide.

Publication Top Notes

Magnetic Resonance Imaging Predictors of Surgical Difficulty in Transforaminal Endoscopic Lumbar Discectomy for Far-Lateral Disc Herniation Under Local Anesthesia

A Commentary on “Full-Endoscopic Resection of a Lumbar Intradural Tumor (Schwannoma): Video Case Report and Description of the Surgical Technique”

Transforaminal Endoscopic Lumbar Foraminotomy for Iatrogenic Foraminal Stenosis Following Vertebroplasty

Access Pain During Transforaminal Endoscopic Lumbar Discectomy for Foraminal or Extraforaminal Disc Herniation

Access Pain during Transforaminal Endoscopic Lumbar Discec-Tomy for Foraminal or Extraforaminal Disc Herniation

Learning Curve for Endoscopic Transsphenoidal Surgery: A Systematic Review and Meta-Analysis

Yu Pan | Medicine and Health Sciences | Young Scientist Award

Published on by Research Hypothesis

Yu Pan | Medicine and Health Sciences | Young Scientist Award

Dr Yu Pan, Fujian Medical University Union Hospital, China

Dr. Yu Pan is a pioneering medical scientist and attending physician at the Department of General Surgery, Fujian Medical University Union Hospital, China. His groundbreaking research bridges immunotherapy and pancreatic cancer treatment, focusing on mechanisms shaping the tumor microenvironment and translating them into clinical applications. As the principal investigator of multiple prestigious grants, Dr. Pan leads a laboratory exploring mRNA vaccine development and immune regulation in pancreatic malignancies. With over a dozen high-impact publications, including in Nature Nanotechnology and JITC, his work is rapidly transforming the therapeutic landscape. An active mentor and educator, he has guided eight Master’s students, several of whom now pursue PhDs or hold clinical positions at top hospitals. Recognized for academic excellence and innovation, Dr. Pan exemplifies the qualities of a future leader in oncology and immunology. His contributions reflect a deep commitment to both science and society.

Publication Profile

Orcid

Education

Dr. Yu Pan is a dedicated medical professional with a strong academic background in Medical Sciences 🧠🔬. He began he journey in medicine at Anhui Medical University, China, where he earned he Bachelor’s degree between 2008 and 2013 🎓🇨🇳. He passion for advancing healthcare led he to pursue further studies at Fujian Medical University. From 2014 to 2017, he completed he Master’s degree in Medical Sciences, specializing in General Surgery 🏥🩺. Demonstrating exceptional commitment to surgical research and clinical excellence, Dr. Pan continued at the same university to obtain her Ph.D. in Medical Sciences from 2017 to 2020 🎓🔍. During her academic career, she gained extensive experience in surgical techniques, research methodologies, and patient care, contributing significantly to the field of general surgery 📚. He educational path reflects a continuous pursuit of knowledge and skill development, underscoring he role as a dedicated surgeon and researcher committed to medical innovation and patient well-being ❤️‍🩹.

Experience

Dr. Yu Pan is a dedicated surgical professional with extensive experience in clinical practice, teaching, and mentorship. From 2020 to 2022, Dr. Pan completed a surgical residency at the Department of Surgery, Fujian Medical University Union Hospital 🏥. Since 2022, he has served as a Staff Attending Physician in the Department of General Surgery 👨‍⚕️. Alongside his clinical duties, Dr. Pan has been actively involved in teaching as an Instructor for Clinical Skills Training Classes (2022–2024) at Fujian Medical University 🎓. He has also served as a thesis advisor for Master’s students since 2021, mentoring eight students in total. Five have graduated, with three pursuing PhDs and two now practicing at top institutions, including Jinhua Hospital and Fudan University Shanghai Cancer Center 🎯. His mentees have published in prestigious journals such as JITC, Functional Integrated Genomics, Frontiers in Pharmacology, and Cell Death & Disease 📚🔬, reflecting Dr. Pan’s strong academic impact.

Awards and Honors

Dr. Yu Pan is a highly accomplished medical researcher recognized for his consistent contributions to science and healthcare advancement 🧬🩺. He currently leads the 2025 Overseas Study Program for Young and Middle-Aged Medical Talents in Fujian Province 🌏✨. In 2023, he was selected for the Excellent Young Scholars Cultivation Project by Fujian Medical University Union Hospital (No. 2022XH025) 🧑‍🔬🏅. His expertise earned national recognition through the prestigious 2021 National Natural Science Foundation of China grant (No. 82103310) 🇨🇳🔍. That same year, he secured funding from the Natural Science Foundation of Fujian Province (No. 2021J01774) and played a pivotal role in the Joint Funds of the Scientific and Technological Innovation Program of Fujian Province (No. 2020Y9081) 💡🔬. Additionally, Dr. Pan led the 2020 Fujian Provincial Health Technology Project (No. 2020GGA029), further highlighting his dedication to medical research and innovation in the region.

Research Focus

Dr. Yu Pan’s research centers on pancreatic cancer and inflammatory-immune responses, with a strong emphasis on immune regulation, tumor microenvironment, and therapeutic targets 🧬🩸. His studies explore the role of Annexin A1, CD47-targeted therapies, and immune checkpoints in pancreatic disorders, especially pancreatic ductal adenocarcinoma (PDAC) and neuroendocrine neoplasms 🧫🧠. Through single-cell analysis, preclinical models, and clinical translation, Dr. Pan investigates how immune dynamics shape disease progression and treatment outcomes 🧪📊. His work contributes significantly to immunotherapy and precision medicine in gastrointestinal oncology, aiming to improve prognosis and treatment for patients with severe pancreatic conditions 💊🧠🧑‍⚕️.

Publication Top Notes

Annexin A1 regulates inflammatory-immune response and reduces pancreatic and extra- pancreatic injury during severe acute pancreatitis

Translating CD47-Targeted Therapy in Gastrointestinal Cancers: Insights from Preclinical to Clinical Studies

The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms

Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway

High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer

Prognostic value of preoperative enhanced computed tomography as a quantitative imaging biomarker in pancreatic cancer

 

Joseph M Pappachan | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Joseph M Pappachan | Medicine and Health Sciences | Best Researcher Award

Prof. Dr Joseph M Pappachan, Manchester Metropolitan University, United Kingdom

Prof. Dr. Joseph M. Pappachan is an internationally acclaimed endocrinologist and physician-scientist with profound contributions to metabolic and endocrine disorders. With over two decades of clinical, academic, and research experience, he currently serves at the Department of Endocrinology, Amrita Institute of Medical Sciences, India. His work bridges the gap between clinical practice and groundbreaking research, particularly in diabetes, obesity, metabolic syndrome, and endocrine hypertension. 📊 He has authored numerous high-impact publications and book chapters, and actively contributes to peer-reviewed journals as an editor and reviewer. Prof. Pappachan’s research is widely cited, reflecting his global influence in the field. 🌍 Known for his mentorship and academic leadership, he has trained many budding endocrinologists and researchers. His dedication to innovation and translational research has earned him multiple accolades and fellowships. 🧪 A dynamic scholar and clinician, Prof. Pappachan embodies excellence, integrity, and impact in the medical research community.

Publication Profile

Google Scholar

Education

Prof. Dr. Joseph M. Pappachan holds an MBBS degree from Government Medical College, Calicut, and completed his MD in Internal Medicine from Government Medical College, Trivandrum. 🏥 He further specialized in Endocrinology with a DM from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi. 📘 In pursuit of global medical standards, he earned Membership of the Royal College of Physicians (MRCP) in the UK and became a Fellow of the Royal College (FRCP) and Fellow of the American College of Endocrinology (FACE). 🎖️ Prof. Pappachan has also undergone advanced training in endocrinology and diabetes in the United Kingdom and Europe, further honing his expertise in clinical research and metabolic diseases. 🌍 His commitment to lifelong learning is evident in his pursuit of continuing medical education and participation in international research fellowships, solidifying his position as an educator and research innovator in the medical sciences.

Experience

With over 20 years in clinical practice and academic research, Prof. Pappachan has served in leading institutions in India and the UK. 🏥 He is currently a Senior Consultant and Professor at the Department of Endocrinology, Amrita Institute of Medical Sciences, Kochi. Previously, he held several academic positions in NHS hospitals and universities across the United Kingdom, where he actively participated in clinical trials and interdisciplinary research. 🌐 His professional journey includes experience in tertiary referral centers for complex endocrine and metabolic disorders. Prof. Pappachan is a sought-after speaker in national and international medical conferences and frequently leads CME programs for physicians. 🗣️ He also serves on the editorial boards of prominent journals and contributes significantly to peer-review processes. 🖋️ His extensive experience in patient care, medical education, and translational research makes him a respected authority in endocrinology worldwide.

Awards and Honors

Prof. Pappachan’s excellence in research has been recognized through numerous awards, fellowships, and international honors. 🏅 He has received the Fellowship of the Royal College of Physicians (FRCP), Fellowship of the American College of Endocrinology (FACE), and prestigious research grants for his work in metabolic disorders. 🎓 His research publications have garnered thousands of citations, and he ranks among the top Indian scientists in endocrinology. 📊 He has served as an expert panel member for international bodies and contributes to the development of clinical guidelines in diabetes and metabolic syndrome. 🌟 As an editorial board member and peer reviewer for several high-impact journals, his insight is valued across the medical research spectrum. 🧬 His outstanding contributions to patient care, research, and academic mentorship have earned him wide acclaim and nominations for top medical awards, making him a truly deserving candidate for the Best Researcher Award.

Research Focus

Prof. Pappachan’s research primarily centers on diabetes mellitus, obesity, metabolic syndrome, thyroid disorders, and hypertension, with a strong emphasis on the interplay between endocrine function and metabolic health. 🔍 His pioneering work investigates mechanisms of insulin resistance, neuroendocrine regulation, and cardiometabolic risk in various populations. His translational research explores clinical applications of novel diagnostic tools, therapeutic strategies, and biomarker discovery. 🧪 He has also examined sleep disorders and circadian rhythm disruptions in metabolic diseases and their implications for treatment outcomes. 🌙 His extensive publications focus on patient-centered interventions and the development of global clinical protocols. 📋 With multidisciplinary collaboration, Prof. Pappachan continues to advance understanding in precision medicine and evidence-based endocrinology, contributing significantly to the global discourse on metabolic and endocrine diseases. 🌐 His research is transformative, clinically relevant, and instrumental in shaping modern endocrine care.

Publication Top Notes

Omega-3 fatty acids: a comprehensive review of their role in health and disease

Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management

Diabetes mellitus and stroke: a clinical update

Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis

High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a cross-sectional multi-centre observational study

Snakebite envenoming in Kerala, South India: clinical profile and factors involved in adverse outcomes

Male obesity-related secondary hypogonadism–pathophysiology, clinical implications and managementMedicine and Health Sciences

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Published on by Research Hypothesis

Jonathan Trent | Medicine and Health Sciences | Lifetime achievement Award

Prof. Dr Jonathan Trent, Sylvester Comprehensive Cancer Center, University of Miami, United States

Prof. Dr. Jonathan Trent is a distinguished oncologist and researcher, specializing in sarcoma and precision medicine. With an MD and PhD from The University of Texas Health Science Center, he has dedicated his career to advancing cancer treatment. As Associate Director of Clinical Research at Sylvester Comprehensive Cancer Center, he leads groundbreaking studies in medical oncology. His leadership in precision medicine has transformed sarcoma treatment strategies. A prolific author, he has contributed to numerous high-impact publications, shaping the future of cancer therapy. Recognized for his mentorship and excellence in patient care, he has received prestigious awards like Sylvester Outstanding Mentor of the Year. His commitment to clinical innovation and translational research continues to impact oncology worldwide.

Publication Profile

Scopus

Education

Prof. Dr. Jonathan Trent earned his BS in 1988 from Southeastern Oklahoma State University, Durant, OK. He then pursued an MD-PhD program at The University of Texas Health Science Center, Houston, TX (1988-1995), where he developed expertise in oncology and medical research. His postgraduate training includes a Clinical Internship (1995-1996) and a Clinical Residency (1997-1999) at the same institution. He further specialized in cancer treatment through a Medical Oncology Fellowship at MD Anderson Cancer Center (1999-2002), where he also served as Chief Fellow. His extensive academic training laid a strong foundation for his groundbreaking research in sarcoma and precision medicine.

Experience

Prof. Dr. Jonathan Trent began his academic career as Assistant Professor (2002-2008) and later Associate Professor (2008-2011) at MD Anderson Cancer Center. He also served as an Adjunct Professor (2014-2015) at its Graduate School of Biomedical Sciences. Since 2013, he has been a Professor of Medicine at the University of Miami, where he is also Associate Director of Clinical Research, Director of the Sarcoma Medical Research Program, and Director of Precision Medicine at Sylvester Comprehensive Cancer Center. His leadership in sarcoma research, clinical trials, and precision oncology has significantly advanced cancer treatment.

Awards and Honors

Prof. Dr. Jonathan Trent has received numerous prestigious awards for his contributions to oncology, including the Sylvester Outstanding Mentor of the Year 🏆 (Miller School of Medicine, 2015), the Outstanding Care Award 🏅 (Sarcoma Alliance, 2012), and the Leadership in Clinical Research 🎖️ (Sylvester Comprehensive Cancer Center). He is an esteemed member of elite professional organizations such as the American Society for Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and The Max Foundation. His dedication to oncology research and patient care has earned him national and international recognition.

Research Focus

Prof. Dr. Jonathan Trent’s research focuses on sarcoma, targeted therapies, and precision oncology. He has played a pivotal role in the development of novel therapies, including TRK fusion inhibitors, CDK7-targeted treatments, and IDH1 mutation-based interventions. His work has significantly improved the understanding of leiomyosarcoma, chondrosarcoma, and desmoid tumors. As Director of Sarcoma Medical Research and Precision Medicine at Sylvester Comprehensive Cancer Center, he integrates genomic profiling and personalized treatment strategies to enhance patient outcomes. His extensive clinical trials and translational research have shaped modern sarcoma therapies, contributing to groundbreaking advancements in oncology.

Publication Top Notes

A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry

Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours

Use of tyrosine kinase inhibitors in patients with GI stromal tumor who are pregnant or considering pregnancy: Driver mutations and circulating tumor DNA

Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER